Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 295.00
Bid: 294.00
Ask: 295.50
Change: -7.00 (-2.32%)
Spread: 1.50 (0.51%)
Open: 300.00
High: 304.00
Low: 291.50
Prev. Close: 302.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

25 Oct 2019 07:00

RNS Number : 0931R
Synthomer PLC
25 October 2019
 

 

October 25th 2019

 

Synthomer plc

Q3 Trading Update

Continued challenges in European SBR market; Revised FY outlook

 

Synthomer plc ("Synthomer" or "the Group") today issues a trading update for the third quarter ("Q3") ended September 30th 2019.

 

Trading

 

The growing weakness in the global economy has created a more challenging backdrop for the Chemical industry. Depressed European industrial activity combined with increased political and economic uncertainties have resulted in an overall slower trading environment throughout Q3.

 

Performance Elastomers

 

In this environment, Nitrile Butadiene Latex (NBR) had another positive quarter with continued growth supported by the additional 90 ktes of capacity introduced during Q4 2018. NBR volumes increased further during Q3 with year-to-date unit margins remaining stable.

 

In SBR, the Group highlighted challenging conditions in Europe at its H1 results in August. Conditions have not improved during Q3 and the Group's Paper segment has also continued to remain particularly weak. Accordingly, management now expect SBR volumes to be approximately 10% behind 2018 and unit margins to also be similarly lower than last year. A review of network utilisation is currently underway and an update on asset re-purposing and cost base will be provided in conjunction with the Full Year results in March 2020.

 

Functional Solutions

 

Notwithstanding the impact of tough market conditions, overall performance was in line with the first nine months of 2018, with lower volumes offset by higher unit margins. The Group expects to see the benefits of additional capacity at Worms (Germany) and Roebuck (USA) continue to come through in line with the investment case.

 

Industrial Specialities

 

Industrial Specialities continued to trade in-line with management expectations. Volumes and margins were broadly flat with the first nine months of 2018.

 

Financial position

 

At 30 September 2019, the Group remained conservatively levered with net debt/EBITDA, excluding the net proceeds of the rights issue, of 1.4x (30 September 2018: 1.4x).

 

Proposed acquisition of Omnova Solutions Inc.

 

Following approval by both sets of shareholders and competition clearance in the US, the transaction remains subject only to regulatory approval from the European and Turkish competition authorities, and the Group continues to target completion in late 2019.

 

There has been no material change to the expected de-leveraging profile of the Enlarged Group as announced at the time of the transaction.

 

Management remain confident of delivering a swift integration and synergies during 2020.

 

2019 Outlook

 

Whilst Synthomer continues to benefit from its strong product portfolio, end market diversification and geographic presence, the slower trading environment is expected to continue through the remainder of the year and into 2020, particularly in Europe.

 

Whilst Functional Solutions and Industrial Specialities are now expected to be in-line with the prior year, with NBR ahead of 2018, results for the Full Year will be adversely impacted by the increased weakness in the European SBR business.

 

If the current weakness in macroeconomic conditions persist through Q4, excluding any impact from the potential acquisition of OMNOVA, the Board expects underlying profit before tax for FY 2019 to be approximately 10% below 2018 and accordingly current consensus expectations*.

 

- Ends -

 

* Teneo compiled Company consensus: FY 2019 underlying profit before tax - £135.3m

 

Enquiries:

 

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, Head of Investor Relations

 

Tel: + 44 1279 436211

Charles Armitstead, Teneo

Tel: + 44 7703 330 269

 

The Company will hold a conference call for investors and analysts at 0800 BST today:

Dial in number: 08003589473 PIN: 25297905#

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUSUWRKUARUAA
Date   Source Headline
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding
30th Jul 201912:59 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:55 pmRNSDirector/PDMR Shareholding
30th Jul 201912:54 pmRNSDirector/PDMR Shareholding
30th Jul 201912:53 pmRNSDirector/PDMR Shareholding
30th Jul 201912:52 pmRNSDirector/PDMR Shareholding
30th Jul 201912:51 pmRNSDirector/PDMR Shareholding
30th Jul 201912:50 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201911:31 amRNSResults of Rump Placing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.